BRAF inhibitors are a class of targeted therapy drugs designed to inhibit the activity of the BRAF protein, a key player in the MAPK/ERK signaling pathway. Mutations in the BRAF gene, particularly the V600E mutation, are known to promote cancer cell growth and division. These inhibitors are specifically effective against cancers with this mutation.
